Superiority of YM598 over atrasentan as a selective endothelin ET_A receptor antagonistYUYAMA, Hironori; NOGUCHI, Yukiko; FUJIMORI, Akira et al.European journal of pharmacology. 2004, Vol 498, Num 1-3, pp 171-177, issn 0014-2999, 7 p.Article

Bosentan therapy for portopulmonary hypertensionHOEPER, M. M; HALANK, M; MARX, C et al.The European respiratory journal. 2005, Vol 25, Num 3, pp 502-508, issn 0903-1936, 7 p.Article

Safety and tolerability of bosentan in adults with Eisenmenger physiologyGATZOULIS, Michael A; ROGERS, Paula; WEI LI et al.International journal of cardiology. 2005, Vol 98, Num 1, pp 147-151, issn 0167-5273, 5 p.Article

Étude EARLYMONTANI, D; HUMBERT, M; SIMONNEAU, G et al.La Lettre du pneumologue. 2009, Vol 12, Num 1-2, pp 11-13, issn 1292-5977, 3 p.Article

Bosentan and warfarin interactionMURPHEY, Lisa M; HOOD, Elizabeth H.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1028-1031, issn 1060-0280, 4 p.Article

Successful Treatment of Systemic-Sclerosis-Related Digital Ulcers with a Selective Endothelin Type A Receptor Antagonist (Sitaxentan)GHOLAM, P; SEHR, T; ENK, A et al.Dermatology (Basel). 2009, Vol 219, Num 2, pp 171-173, issn 1018-8665, 3 p.Article

La découverte du bosentan = The discovery of bosentanCLOZEL, M.Annales de cardiologie et d'angéiologie (Paris). 2007, Vol 56, issn 0003-3928, S88-S92, SUP3Article

Survival with first-line bosentan in patients with primary pulmonary hypertensionMCLAUGHLIN, V. V; SITBON, O; BADESCH, D. B et al.The European respiratory journal. 2005, Vol 25, Num 2, pp 244-249, issn 0903-1936, 6 p.Article

Traitement de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothélineCACOUB, Patrice.MT. Médecine thérapeutique. 2009, Vol 15, Num 1, pp 8-14, issn 1264-6520, 7 p.Article

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)RAGHU, G; KING, T. E; BEHR, J et al.The European respiratory journal. 2010, Vol 35, Num 1, pp 118-123, issn 0903-1936, 6 p.Article

Role of endothelin-1 in renal regulation of acid-base equilibrium in acidotic humansPALLINI, Alexandra; HULTER, Henry N; MUSER, Jurgen et al.American journal of physiology. Renal physiology. 2012, Vol 72, Num 4, issn 1931-857X, F991-F999Article

Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like pictureDWYER, N; SMITH, R; CHALLIS, D et al.The European respiratory journal. 2009, Vol 33, Num 3, pp 666-669, issn 0903-1936, 4 p.Article

Successful bosentan treatment of critical ischaemia induced by vasculitis in an SCLE patientTHONHOFER, R; SIEGEL, C; HAFNER, F et al.Rheumatology (Oxford. Print). 2008, Vol 47, Num 11, pp 1729-1730, issn 1462-0324, 2 p.Article

Persistent painful indurated erythema secondary to bosentanGALLARDO, Fernando; GIL, Ayoze; COMIN, Josep et al.Acta dermato-venereologica. 2006, Vol 86, Num 2, pp 186-187, issn 0001-5555, 2 p.Article

Bosentan: A novel agent for the treatment of pulmonary arterial hypertensionO'CALLAGHAN, Dermot; GAINE, Sean P.International journal of clinical practice (Esher). 2004, Vol 58, Num 1, pp 69-73, issn 1368-5031, 5 p.Article

Successful Treatment of Sarcoidosis-Associated Pulmonary Hypertension with BosentanFOLEY, Raymond J; METERSKY, Mark L.Respiration (Basel). 2008, Vol 75, Num 2, pp 211-214, issn 0025-7931, 4 p.Article

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2MANO, Yuji; USUI, Takashi; KAMIMURA, Hidetaka et al.Biopharmaceutics & drug disposition. 2007, Vol 28, Num 1, pp 13-18, issn 0142-2782, 6 p.Article

Role of endothelin in fibrosis and anti-fibrotic potential of bosentanCLOZEL, Martine; SALLOUKH, Hashem.Annals of medicine (Helsinki). 2005, Vol 37, Num 1, pp 2-12, issn 0785-3890, 11 p.Article

Endothelin and Pulmonary arterial hypertensionBRAUN-MOSCOVICI, Yolanda; NAHIR, A. Menahem; BALBIR-GURMAN, Alexandra et al.Seminars in arthritis and rheumatism. 2004, Vol 34, Num 1, pp 442-453, issn 0049-0172, 12 p.Article

Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteriesMILARA, J; GABARDA, E; JUAN, G et al.The European respiratory journal. 2012, Vol 39, Num 4, pp 927-938, issn 0903-1936, 12 p.Article

Bosentan, a selective and more potent antagonist for Atractaspis envenomation than the specific antivenomABD-ELSALAM, M. A.Toxicon (Oxford). 2011, Vol 57, Num 6, pp 861-870, issn 0041-0101, 10 p.Article

Rationale and design of a trial on the role of bosentan in Fontan patients: Improvement of exercise capacity?SCHUURING, Mark J; VIS, Jeroen C; BOUMA, Berto J et al.Contemporary clinical trials. 2011, Vol 32, Num 4, pp 586-591, issn 1551-7144, 6 p.Article

Greater Functional ET_B Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy MenMACINTYRE, Iain M; DHAUN, Neeraj; LILITKARNTAKUL, Pajaree et al.Hypertension (Dallas, Tex. 1979). 2010, Vol 55, Num 6, pp 1406-1411, issn 0194-911X, 6 p.Article

Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart diseaseBENZA, Raymond L; RAYBURN, Barry K; TALLAJ, Jose A et al.Chest. 2006, Vol 129, Num 4, pp 1009-1015, issn 0012-3692, 7 p.Article

Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in childrenROLDAN, Rosa; MOROTE, Guadalupe; CASTRO, Maria Del Carmen et al.Journal of rheumatology. 2006, Vol 33, Num 12, pp 2538-2540, issn 0315-162X, 3 p.Article